pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Copiktra
drug · small molecule
save

duvelisib

Marketedupdated 3mo ago
by Secura Bio Inc🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval36 co-mentions · 9 sources
  • tagSmall Molecule18 co-mentions · 9 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 15 investigational indications.

targets

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform

all catalysts(0)

nothing on the calendar yet

Trials studying duvelisib

  • phase1A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)recruitingn=30
  • phase3A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotyperecruitingn=124
  • phase2Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSactive not recruitingn=55
  • phase1Duvelisib Following Chimeric Antigen Receptor T-Cell Therapyactive not recruitingn=42
  • phase2Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomasactive not recruitingn=17
  • phase2Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanomaterminatedn=13
  • phase1Duvelisib in Combination With BMS-986345 in Lymphoid Malignancycompletedn=14
  • phase2Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCCcompletedn=26
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Jan 5, 2029
~2.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

  • Apr 26, 2035method-of-use (U-2412)US 12213983
  • Apr 26, 2035method-of-use (U-2412)US 12213983
  • Sep 24, 2032compositionUS 8193182
  • Sep 24, 2032compositionUS 8193182
  • May 17, 2032compositionUS RE46621
  • May 17, 2032compositionUS RE46621
  • Jan 10, 2032formulationUS 11312718
  • Jan 10, 2032formulationUS 11312718
  • Jan 10, 2032method-of-use (U-2412)US 9840505
  • Jan 10, 2032method-of-use (U-2413)US 9840505
  • Jan 5, 2029method-of-use (U-2412)US 92169822.4y
  • Jan 5, 2029method-of-use (U-2412)US 92169822.4y

News(0)

no news has mentioned this drug yet

brand
Copiktra
generic
duvelisib
MOA
PI3-kinase p110-gamma subunit inhibitor; PI3-kinase p110-delta subunit inhibitor
indication
T-Cell Lymphomas
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 40m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?